AllAnalyst Report
Morningstar•May 06, 2021
Morningstar•May 06, 2021Coloplast A/S: Coloplast Faces Pandemic-Driven Disruption to Patient Flow; No Change to Our Fair Value Estimate
Summary
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy-care systems, disposable containment devices, paste, powder, seals, and wipes. Coloplast also maintains a tertiary presence in the urology and wound-care markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dres
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Analyst Report: Merck KGaAApr 10, 2024 •
MKKGY
- Analyst Report: Merck KGaAMar 07, 2024 •
MKKGY
- Analyst Report: Compass Group PLCFeb 08, 2024 •
CMPGY
- Analyst Report: Compass Group PLCJan 29, 2024 •
CMPGY
- Analyst Report: Merck KGaADec 06, 2023 •
MKKGY
Analyst Profile
Debbie Wang
Senior Equity AnalystDebbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device industry. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald/s, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.